Liver stiffness change with HCV cure in HIV-infected patients on non-nucleoside analogues.
In: Journal of Antimicrobial Chemotherapy (JAC), Jg. 76 (2021-09-01), Heft 9, S. 2375-2379
academicJournal
Zugriff:
Background: Liver stiffness (LS) at sustained viral response (SVR) is strongly associated with a lower incidence of subsequent hepatic events. HIV NNRTIs may have a beneficial impact on fibrogenesis. Objectives: Our aim was to analyse the influence of NNRTI-based therapy on the change in LS from starting direct-acting antiviral (DAA) therapy to achieving SVR in HIV/HCV-coinfected patients. Methods: Three hundred and thirteen HIV/HCV-coinfected patients who fulfilled the following criteria were included: (i) had achieved SVR with an IFN-free, DAA-including regimen; (ii) LS ≥9.5 kPa before therapy; (iii) LS measurement available at SVR; (iv) seronegative for HBsAg; and (v) ART containing 2 NRTIs plus either 1 NNRTI or 1 integrase inhibitor (INI) or 1-2 NRTIs plus 1 PI. LS changes were assessed. Results: Seventy-four patients received NNRTI-based combinations [53 (71.6%) rilpivirine and 16 (21.6%) efavirenz] and 239 patients received other regimens. At baseline, the median (IQR) LS was 16.7 kPa (11.8-25.6) in the NNRTI group and 17.3 kPa (11.9-27.4) in the non-NNRTI group (P = 0.278). The median (IQR) percentage of LS decrease from baseline to SVR was 35.2% (18.2%-52.3%) for NNRTI-based therapy and 29.5% (10%-45.9%) for PI- or INI-based therapy (P = 0.018). In multivariate analysis, adjusted for sex, age, HCV genotype, NRTI backbone and propensity score for HIV therapy, NNRTI-based regimen use was associated with a higher LS decrease [β = 11.088 (95% CI = 1.67-20.51); P = 0.021]. Conclusions: Treatment with NNRTI plus 2 NRTI combinations is associated with a higher LS decline than other ART combinations in HIV/HCV-coinfected patients receiving DAA-based therapy. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Antimicrobial Chemotherapy (JAC) is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Liver stiffness change with HCV cure in HIV-infected patients on non-nucleoside analogues.
|
---|---|
Autor/in / Beteiligte Person: | Gonzalez-Serna, A. ; Corma-Gomez, A. ; Tellez, F. ; García-Martin, S. ; Rivero-Juarez, A. ; Frias, M. ; Vera-Méndez, F. J. ; Santos, I. De los ; Merino, D. ; Morano, L. ; Imaz, A. ; Galera, C. ; Serrano, M. ; Macias, J. ; Pineda, J. A. ; De Los Santos, I |
Zeitschrift: | Journal of Antimicrobial Chemotherapy (JAC), Jg. 76 (2021-09-01), Heft 9, S. 2375-2379 |
Veröffentlichung: | 2021 |
Medientyp: | academicJournal |
ISSN: | 0305-7453 (print) |
DOI: | 10.1093/jac/dkab157 |
Schlagwort: |
|
Sonstiges: |
|